WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

Search

Hims & Hers Health Inc

Fechado

SetorConsumo Básico

31.15 0.48

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.94

Máximo

31.21

Indicadores-chave

By Trading Economics

Rendimento

-50M

26M

Vendas

80M

481M

P/E

Médio do Setor

54.722

44.466

EPS

0.227

Margem de lucro

5.409

Funcionários

1,637

EBITDA

-8.2M

19M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+49.76% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4.7B

6.5B

Abertura anterior

30.67

Fecho anterior

31.15

Sentimento de Notícias

By Acuity

18%

82%

9 / 152 Ranking em Consumer defensive

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Hims & Hers Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de abr. de 2025, 23:15 UTC

Grandes Movimentos do Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 de fev. de 2025, 15:33 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 de nov. de 2024, 19:07 UTC

Grandes Movimentos do Mercado

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 de out. de 2024, 15:02 UTC

Grandes Movimentos do Mercado

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 de out. de 2024, 11:28 UTC

Grandes Movimentos do Mercado

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2 de abr. de 2025, 16:53 UTC

Principais Notícias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 de mar. de 2025, 15:54 UTC

Principais Notícias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 de fev. de 2025, 23:20 UTC

Ganhos

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 de fev. de 2025, 12:00 UTC

Principais Notícias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 de dez. de 2024, 17:16 UTC

Principais Notícias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 de dez. de 2024, 15:14 UTC

Principais Notícias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 de dez. de 2024, 15:02 UTC

Principais Notícias

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 de dez. de 2024, 13:47 UTC

Principais Notícias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 de dez. de 2024, 07:00 UTC

Principais Notícias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 de out. de 2024, 14:45 UTC

Principais Notícias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 de out. de 2024, 13:12 UTC

Principais Notícias

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 de out. de 2024, 11:45 UTC

Principais Notícias

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 de out. de 2024, 10:14 UTC

Principais Notícias

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 de ago. de 2024, 17:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 de jun. de 2024, 11:00 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 de mai. de 2024, 20:37 UTC

Ganhos

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Comparação entre Pares

Variação de preço

Hims & Hers Health Inc Previsão

Preço-alvo

By TipRanks

49.76% parte superior

Previsão para 12 meses

Média 46.5 USD  49.76%

Máximo 85 USD

Mínimo 21 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Hims & Hers Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

13 ratings

5

Comprar

6

Manter

2

Vender

Pontuação Técnica

By Trading Central

31.0237 / 31.88Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

9 / 152 Ranking em Consumo Básico

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.